Hummer Financial Advisory Services Inc Sells 100 Shares of Johnson & Johnson (NYSE:JNJ)

Hummer Financial Advisory Services Inc lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,417 shares of the company’s stock after selling 100 shares during the quarter. Johnson & Johnson comprises 1.2% of Hummer Financial Advisory Services Inc’s portfolio, making the stock its 16th biggest holding. Hummer Financial Advisory Services Inc’s holdings in Johnson & Johnson were worth $1,507,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC increased its stake in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after acquiring an additional 91 shares during the last quarter. Activest Wealth Management bought a new stake in Johnson & Johnson in the 3rd quarter worth approximately $40,000. Finally, Morton Brown Family Wealth LLC increased its stake in Johnson & Johnson by 400.0% in the 3rd quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock worth $41,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Bank of America reaffirmed a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Guggenheim lifted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $144.68 on Wednesday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a market capitalization of $348.33 billion, a price-to-earnings ratio of 20.94, a P/E/G ratio of 2.52 and a beta of 0.51. The stock has a fifty day simple moving average of $149.12 and a two-hundred day simple moving average of $156.09. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the business earned $2.66 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.